Uusalo, P. http://orcid.org/0000-0001-5120-8854
Al-Ramahi, D.
Tilli, I.
Aantaa, R. A.
Scheinin, M.
Saari, T. I.
Funding for this research was provided by:
Varsinais-Suomen Sairaanhoitopiiri (13693)
Varsinais-Suomen Sairaanhoitopiiri (13821)
Article History
Received: 20 December 2017
Accepted: 5 April 2018
First Online: 17 April 2018
Compliance with ethical standards
: The study protocol (EudraCT 2015-004698-34, ExternalRef removed identifier NCT02724098) conformed to the revised Declaration of Helsinki [CitationRef removed] and was approved by the Ethics Committee of the Hospital District of Southwest Finland and by the Finnish National Agency for Medicines. Written informed consent was obtained from all study participants.
: M. Scheinin has been engaged in contract research for Orion Pharma, the manufacturer of dexmedetomidine. T. Saari has received honoraria for speaking at symposia organized by Orion Pharma. P. Uusalo has received a speaker’s fee from Orion Pharma. D. Al-Ramahi is currently employed by Orion Pharma, but had no affiliation with the company at the time of this study. The other authors declare no conflicts of interest.